Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

Discover Alabama's 2026 football commits and stay informed about recruitment updates and player commitments for the upcoming season.